Expres2ion Biotech Holding Ab · OMXSTO:EXPRS2
Expres2ion Biotech Holding Ab — Q4 2021 Earnings Presentation
21 slides from Expres2ion Biotech Holding Ab's earnings presentation, Feb 24, 2022
Slide 1: Q4 2021 Financial Report
Q4 2021 Financial Report February 24, 2022 Proteins for Life Bent U. Frandsen, CEO Keith Alexander, CFO
Slide 2: Disclaimer
Disclaimer This company presentation (the ”Company Presentation”), which is personal to the recipient, is issued by ExpreS2ion Biotech Holding AB (the “Company”). The Company Presentation has been prepared for information purposes only and is not to be relied upon in substitution for the exercise of
Slide 3: Investment Highlights
Investment Highlights Key player in advanced protein sciences, with deep pipeline of novel vaccines addressing high- value markets High-potential pipeline of key focus, backed up by Contract Research Organization (CRO) business, that has generated SEK 60 million since IPO in 2016 Vaccine development
Slide 4: ABNCoV2 COVID-19 Vaccine (I)
CORONAVIRUS ABNCoV2 COVID-19 Vaccine (I) Phase I/IIa study confirms safety and tolerability and excellent efficacy profile ABNCoV2 induces high neutralization High virus neutralization levels were antibody titers shown across COVID-19 variants • Dose response: increased titers with higher vaccine do
Slide 5: ABNCoV2 COVID-19 Vaccine (II)
CORONAVIRUS ABNCoV2 COVID-19 Vaccine (II) Bavarian Nordic carries on with the Phase II study, and granted DKK 800m funding for Phase III Phase II study design Phase II study topline results (1/3 groups) • Evaluate ABNCoV2 as a booster vaccine in individuals with existing • First of three groups in t
Slide 6: Partnership with Bavarian Nordic
CORONAVIRUS Partnership with Bavarian Nordic ABNCoV2 is already out-licensed with near-term revenue streams supporting ExpreS2ion AdaptVac receive from Bavarian Nordic ExpreS2ion receive from AdaptVac • EUR 4 million upfront (paid in July 2020) • 34% ownership of AdaptVac • Up to EUR 136 million in
Slide 7: ES2B-C001 Overcomes Herceptin Resistance
BREAST CANCER ES2B-C001 Overcomes Herceptin Resistance The soft agar human cancer cell growth inhibition assay provides in vitro evidence UNTREATED ES2B-C001 Trastuzumab- sensitive HER2+ human cancer cells1 Both Herceptin (trastuzumab) and ES2B-C001 inhibited growth in the trastuzumab-sensitive cell
Slide 8: ES2B-C001 Preclinical Proof-of-Concept
BREAST CANCER ES2B-C001 Preclinical Proof-of-Concept ES2B-C001 has demonstrated animal proof-of-concept Effectively inhibited tumor development Prevented tumor development with 95% efficiency *p<0.05 at least ES2B-C001+Adjuvant SchA vs. Other groups from day 52, Tukey’s test ES2B-C001+ Adjuvant n=20
Slide 9: Advancing Towards Key Catalysts
Advancing Towards Key Catalysts 2022 2023 2024 CORONAVIRUS (ABNCoV2) BN Phase II BN Phase II BN Phase III BN Phase III BN ready for study initiation study readout study initiation initial readout market launch (Q3’21) H1 2022 H1 2022 H2 2022 (subject to regulatory approval) BREAST CANCER (ES2B-C001)
Slide 10: Management Team
Management Team Experienced team driving pipeline-focused business Bent U. Frandsen, CEO Dr. Mette Thorn, VP Preclinical Development • MSc. In Finance/Strategic Management, Copenhagen Business School, • PhD in Immunology, and a MSc in Chem Eng., Tech. Univ of Denmark Denmark • 20 years industrial re
Slide 11: Q4 2021 Financial Results
Q4 2021 Financial Results Proteins for Life
Slide 12: Operating income
FINANCE Operating income Operating income, SEK ‘000s Net sales, SEK ‘000s Other operating income, SEK ‘000s 6,000 5,000 5,000 4,500 5,000 4,000 4,000 4,000 3,500 3,000 = 3,000 + 3,000 2,500 2,000 2,000 2,000 1,500 1,000 1,000 1,000 500 0 1Q19 2Q19 3Q19 4Q19 1Q202Q203Q204Q20 1Q21 2Q21 3Q21 4Q21 0 0 N
Slide 13: Operating costs
FINANCE Operating costs Operating costs, SEK ‘000s 4Q Operating costs, SEK ‘000s YTD Operating costs, SEK ‘000s 4Q19 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21 3Q21 4Q21 0 0 0 -10,000 -3,000 -5,000 -6,000 -20,000 -9,000 -10,000 -30,000 -12,000 -40,000 -15,000 -15,000 -46,459 -50,000 -18,000 -20,000 +34% -8% -20,
Slide 14: Profit / loss for the period
FINANCE Profit / loss for the period 4Q profit / loss, SEK ‘000s YTD profit / loss, SEK ‘000s 2020 2021 2020 2021 0 0 -3,000 -7,000 -6,000 -14,000 -9,000 -21,000 -12,000 -28,000 +39% -31,713 -15,000 -14,320 -35,000 -17% -18,000 -17,353 -42,000 -43,925 -21,000 -49,000 Proteins for Life | 14
Slide 15: Cash balance
FINANCE Cash balance SEK millions 160 + SKAT 142 138 balance 140 120 107 108 100 83 80 60 37 Cash and 40 30 equivalents 20 10 13 5 3 5 6 0 1Q19 2Q19 3Q19 4Q19 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21 3Q21 4Q21 Proteins for Life | 15
Slide 16: 2021 Cash development
FINANCE 2021 Cash development Cash development including SKAT balance, SEK millions 200 75 -46 160 2 138 120 107 80 40 0 Dec-20 New Capital Ops/Inv FX Dec-21 Proteins for Life
Slide 17: Shareholder Composition
FINANCE Shareholder Composition During 2021 No. of shareholders grows from ~6,000 to ~14,000 No. of shareholders No. of shares outstanding 16,000 35,000,000 14,000 30,000,000 12,000 25,000,000 10,000 20,000,000 8,000 15,000,000 6,000 10,000,000 4,000 2,000 5,000,000 0 0 3Q19 4Q19 1Q20 2Q20 3Q20 4Q20
Slide 18: Thank you!
Thank you! Contact: info@expreS2ionbio.com Proteins for Life
Slide 19: Our Technology
Our Technology Proteins for Life
Slide 20: ExpreS Platform for Complex Proteins
2 ExpreS Platform for Complex Proteins Enables unique non-viral approach to protein and vaccine production Transfection of desired gene into S2 cells, including secretion signal: 1 week Reducing risks in discovery manufacturing Cell line derived from Drosophila melanogaster ✓ Fast & high level prote
Slide 21: Virus Like Particle (VLP) Technology
Virus Like Particle (VLP) Technology VLP technology has proven track record in cancer vaccine applications (HPV) Our ExpreS2 platform produces the High immunogenic potential complex surface proteins (antigens), • Full length proteins: Exceptionally strong which are critical to immune system attachme
ExpreS2ion Biotech Holding — Q4 2021 Earnings Presentation on 6ix